Insight Molecular Diagnostics Inc. (IMDX) — Strategic Asset Allocation Index
Insight Molecular Diagnostics Inc. (IMDX) has a Strategic Asset Allocation Index of 0.0% as of December 2021. Strategic assets (PP&E of $- plus long-term investments of $0.00) total $0.00, measured against net assets of $65.22 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See IMDX equity to assets ratio to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Insight Molecular Diagnostics Inc. Strategic Asset Allocation Index (2021–2021)
This chart shows how Insight Molecular Diagnostics Inc.'s Strategic Asset Allocation Index has evolved across 1 annual periods from 2021 to 2021. As of December 2021, the index stands at 0.0%, representing strategic assets of $0.00 against net assets of $65.22 Million USD. For live market cap and overall valuation, see Insight Molecular Diagnostics Inc. stock valuation.
Annual Strategic Asset Allocation Index for Insight Molecular Diagnostics Inc. (2021–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for Insight Molecular Diagnostics Inc. from 2021 to 2021, covering 1 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See Insight Molecular Diagnostics Inc. (IMDX) net assets for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 0.0% | $0.00 | $- | $0.00 | $65.22 Million | — |